A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Trial Profile

A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2015

At a glance

  • Drugs AZD 5069 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Acronyms CIRRUS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Planned End Date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top